Abstract: It is very important to evaluate the fetal safety of drugs of the controlled ovarian stimulation (COS) in infertility treatment. The available data suggested that COS drugs did not increase the rate of birth defects. There was not evidence to show that COS drugs had obvious teratogenic effects. In fact, infertility itself may be one of the risk factors for congenital malformation. In this review, we briefly introduced COS drugs, their teratogenic effects on offsprings, as well as malformation types.

Key words: Infertility, female, Superovulation, Congenital abnormalities, Drug monitoring, Gonadotropin?-releasing hormone, Gonadotropins